Safety and efficacy of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: Results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (ATLAST) trial
- 1 May 2002
- journal article
- clinical trial
- Published by Elsevier in American Heart Journal
- Vol. 143 (5) , 841-846
- https://doi.org/10.1067/mhj.2002.121929
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Timing of coronary stent thrombosis in patients treated with ticlopidine and aspirinThe American Journal of Cardiology, 1999
- Incidence and Clinical Course of Thrombotic Thrombocytopenic Purpura Due to Ticlopidine Following Coronary StentingJAMA, 1999
- Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement.Circulation, 1999
- A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery StentingNew England Journal of Medicine, 1998
- Randomized Multicenter Comparison of Conventional Anticoagulation Versus Antiplatelet Therapy in Unplanned and Elective Coronary StentingCirculation, 1998
- Low-molecular-weight heparins in coronary stenting (the ENTICES trial)The American Journal of Cardiology, 1998
- A Randomized Comparison of Antiplatelet and Anticoagulant Therapy after the Placement of Coronary-Artery StentsNew England Journal of Medicine, 1996
- A Randomized Comparison of Combined Ticlopidine and Aspirin Therapy Versus Aspirin Therapy Alone After Successful Intravascular Ultrasound–Guided Stent ImplantationCirculation, 1996
- Antiplatelet DrugsDrugs, 1995
- Intracoronary stenting without coumadin: One month results of a French multicenter studyCatheterization and Cardiovascular Diagnosis, 1995